Floatz logo

NPA C-11

Major Depression

New York State Psychiatric InstituteSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Major Depression cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
Amitriptyline
e-Therapeutics PLC
Phase 4BBB
MELIPRAMINE
Hospital de Clinicas de Porto Alegre
Phase 4BBB
Riluzole
Brigham and Women's Hospital
Phase 4BB

View all 44 →

Same molecule, other indications

NPA C-11 is also rated in:

DementiaDormant
B
Indicative ·
62 / 100
View asset →
Alzheimer DiseaseDormant
B
Indicative ·
56 / 100
View asset →
schizophreniaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →